As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones ...

Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life sciences sector.

TECH expands via acquisitions and global growth, but biotech funding softness, U.S. academic spending pressure and ...

Bio-Techne (TECH) is back in focus after institutional investors such as Jefferies Financial Group and Madison Investments ...

Bio-Techne Corp. closed 27.94% short of its 52-week high of $72.16, which the company achieved on January 22nd.

In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...